Projects

Title Yearsort descending
X Congreso Nacional de Micobacterias - MycoZAR 2017 - 2018
Estrategias innovadoras de reposicionamiento de fármacos para la identificación de nuevas terapias contra las infecciones causadas por micobacterias no tuberculosas en pacientes de Fibrosis Quística. 2018 - 2018
Desarrollo de modelos farmacológicos para la predicción de terapias óptimas que incluyan beta-lactámicos en el tratamiento de la tuberculosis 2018 - 2018
Identification of novel therapies for difficult to treat cystic fibrosis pulmonary infections caused by mycobacteria using an innovative technology: synergy screens of clinically approved drugs 2018 - 2019
Predicting optimal partners, combinatorial dosing schedules and clinical outcomes of beta-lactams using PKPD and mechanistic in vitro models 2018 - 2020
Beta-lactams for Tuberculosis Treatment 2018 - 2020
Discovery and development of tigecycline enhancer in Klebsiella pneumoniae 2018 - 2018
DESARROLLO DE NUEVAS TERAPIAS ANTIMICROBIANAS MEDIANTE EL REPOSICIONAMIENTO DE FÁRMACOS EN COMBINACIONES SINÉRGICAS Y MODELOS DINÁMICOS FARMACOLÓGICOS: IMPLEMENTANDO UNA NUEVA TECNOLOGÍA INNOVADORA EN ARAGÓN 2019 - 2020
EUROPEAN REGIMEN ACCELERATOR FOR TUBERCULOSIS 2020 - 2023
BCG revaccination for healthcare workers in SARS-CoV-2 pandemic 2020 - 2022
Designing optimal regimes for tuberculosis therapy using one-step high content dynamic in vitro kill kinetic assay linked to hollow fibre studies. 2020 - 2022
Beta-lactam containing regimen for the shortening of Buruli ulcer disease therapy: comparison of 8 weeks standard therapy (rifampicin plus clarithromycin) vs. 4 weeks standard plus amoxicillin/clavulanate therapy [RC8 vs. RCA4]. 2020 - 2023
New Weapons Against Mycobacterium abscessus and other Non-Tuberculous Mycobacteria 2020 - 2021
Desarrollo de un modelo 3D de infección por SARS-CoV-2 de organoides primarios pulmonares humanos como plataforma de ensayo para nuevas terapias anti-COVID19 2020 - 2021
Screening of the FDA approved drug library with a primary human 3D Lung Organoid Model of SARS- CoV-2 infection 2020 - 2021
New Weapons Against Mycobacterium abscessus and other Non-Tuberculous Mycobacteria (Project extension) 2021 - 2022
Shortening Buruli Ulcer treatment: WHO recommended vs. a novel beta-lactam-containing therapy - Phase III evaluation in West Africa 2021 - 2025
Understanding the contribution of Kaftrio to antimicrobial therapies against non-tuberculous mycobacteria in cystic fibrosis 2024 - 2026